{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:41:51Z","timestamp":1793943711889,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In the primary analysis (32.3-month median follow-up) of the randomized, phase 3 AURIGA study (NCT03901963), daratumumab-lenalidomide (D-R) maintenance significantly improved MRD-negative conversion rates and reduced the risk of disease progression or death by 47% versus R maintenance in anti-CD38 monoclonal antibody\u2013na\u00efve and post-transplant MRD-positive patients with newly diagnosed MM. Here, we present a post hoc analysis across relevant subgroups, including high-risk cytogenetic abnormalities (HRCAs) per original, revised, and modified International Myeloma Society (IMS) 2024 criteria. MRD-negative (10<jats:sup>\u22125<\/jats:sup>) conversion rates by 12 months of maintenance were higher for D-R versus R across cytogenetically high-risk subgroups per original (31.8% vs 6.7%), revised (43.8% vs 13.3%), and modified IMS 2024 (41.2% vs 0%) criteria and cytogenetically ultra-high\u2013risk disease (\u22652 revised HRCAs; 54.5% vs 0%). Similar trends in overall MRD-negative conversion rates were observed across subgroups. D-R demonstrated a trend towards improved PFS versus R (HR [95% CI]) in cytogenetically high-risk subgroups per original (0.60 [0.21\u20131.70]), revised (0.53 [0.21\u20131.31]), and modified IMS 2024 (0.45 [0.13\u20131.53]) criteria and cytogenetically ultra-high\u2013risk disease (0.61 [0.17\u20132.25]). Similar outcomes were observed regardless of age or race, with no additional safety concerns among older (\u226565 years) or Black patients. These data support the benefit of D-R maintenance regardless of age, race, and risk status.<\/jats:p>","DOI":"10.1038\/s41408-025-01355-0","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:07:28Z","timestamp":1759759648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-1634","authenticated-orcid":false,"given":"Laahn","family":"Foster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-2217","authenticated-orcid":false,"given":"Chakra P.","family":"Chaulagain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Pettijohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Silbermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Krevvata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Khare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelore","family":"Cortoos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Badros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"1355_CR1","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840\u20138.","journal-title":"J Immunol"},{"key":"1355_CR2","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","volume":"124","author":"J Lammerts van Bueren","year":"2014","unstructured":"Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124:3474.","journal-title":"Blood"},{"key":"1355_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, B\u00f6gels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7:311\u201321.","journal-title":"MAbs"},{"key":"1355_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking. J Immunol. 2016;197:807\u201313.","journal-title":"J Immunol"},{"key":"1355_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384\u201394.","journal-title":"Blood"},{"key":"1355_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cyto.a.23693","volume":"95","author":"HC Adams III","year":"2019","unstructured":"Adams HC III, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, et al. High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A. 2019;95:279\u201389.","journal-title":"Cytometry A"},{"key":"1355_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","volume":"35","author":"T Casneuf","year":"2021","unstructured":"Casneuf T, Adams HC III, van de Donk NWCJ, Abraham Y, Bald J, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. 2021;35:573\u201384.","journal-title":"Leukemia"},{"key":"1355_CR8","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104\u201315.","journal-title":"N Engl J Med"},{"key":"1355_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301\u201313.","journal-title":"N Engl J Med"},{"key":"1355_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395:132\u201341.","journal-title":"Lancet"},{"key":"1355_CR11","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.21.02734","volume":"41","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41:1600\u20139.","journal-title":"J Clin Oncol"},{"key":"1355_CR12","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41:1590\u20139.","journal-title":"J Clin Oncol"},{"key":"1355_CR13","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","volume":"25","author":"P Moreau","year":"2024","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024;25:1003\u201314.","journal-title":"Lancet Oncol"},{"key":"1355_CR14","unstructured":"DARZALEX\u00ae (daratumumab) [package insert]. Horsham, PA: Janssen Biotech, Inc.; April 2025."},{"key":"1355_CR15","unstructured":"DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) [package insert]. Horsham, PA: Janssen Biotech; July 2024."},{"key":"1355_CR16","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825\u201337.","journal-title":"Lancet Haematol"},{"key":"1355_CR17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study. Nat Med. 2025;31:1195\u2013202.","journal-title":"Nat Med"},{"key":"1355_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1182\/blood.2024025746","volume":"145","author":"AZ Badros","year":"2025","unstructured":"Badros AZ, Foster L, Anderson LD Jr, Chaulagain CP, Pettijohn EM, et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025;145:300\u201310.","journal-title":"Blood"},{"key":"1355_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/hematology.2021000229","volume":"2021","author":"MV Mateos","year":"2021","unstructured":"Mateos MV, Martinez BP, Gonzalez-Calle V. High-risk multiple myeloma: how to treat at diagnosis and relapse? Hematology Am Soc Hematol Educ Program. 2021;2021:30\u20136.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1355_CR20","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","volume":"115","author":"I Hanamura","year":"2022","unstructured":"Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. 2022;115:762\u201377.","journal-title":"Int J Hematol"},{"key":"1355_CR21","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"R Fonseca","year":"2009","unstructured":"Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210\u201321.","journal-title":"Leukemia"},{"key":"1355_CR22","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086\u2013107.","journal-title":"Am J Hematol"},{"key":"1355_CR23","unstructured":"Moreau P. Opening Ceremony President\u2019s Address. Presented at the International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024; Rio de Janeiro, Brazil."},{"key":"1355_CR24","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43:2739\u201351.","journal-title":"J Clin Oncol"},{"key":"1355_CR25","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol.2016;17:e328\u201346.","journal-title":"Lancet Oncol."},{"key":"1355_CR26","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.2022017863","volume":"141","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, et al. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood. 2023;141:1308\u201315.","journal-title":"Blood"},{"key":"1355_CR27","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood.2020008346","volume":"137","author":"J Corre","year":"2021","unstructured":"Corre J, Perrot A, Caillot D, Belhadj K, Hulin C, Leleu X, et al. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood. 2021;137:1192\u20135.","journal-title":"Blood"},{"key":"1355_CR28","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"1355_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01088-6","volume":"14","author":"A Chari","year":"2024","unstructured":"Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024;14:107.","journal-title":"Blood Cancer J"},{"key":"1355_CR30","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Sonneveld P, Rodr\u00edguez-Otero P, Quach H, Ho PJ, Beksac M, et al. Daratumumab (DARA)\/bortezomib\/lenalidomide\/dexamethasone (D-VRd) with D-R maintenance (maint) in transplant-eligible (TE) newly diagnosed myeloma (NDMM): PERSEUS cytogenetic risk analysis. Presented at the International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024; Rio De Janeiro, Brazil.","DOI":"10.1016\/S2152-2650(24)01889-5"},{"key":"1355_CR31","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hajek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:1597\u2013609.","journal-title":"N Engl J Med"},{"key":"1355_CR32","doi-asserted-by":"crossref","unstructured":"Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): clinical assessment of key subgroups of the phase 3 MAIA study. Presented at the American Society of Hematology (ASH) Annual Meeting & Exposition; December 10-13, 2022; New Orleans, LA, USA.","DOI":"10.1182\/blood-2022-163494"},{"key":"1355_CR33","unstructured":"Facon T, Kumar SK, Orlowski RZ, Bahlis N, Moreau P, Goldschimdt H, et al. Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA study. Presented at the European Hematology Association (EHA) Hybrid Congress; June 13-16, 2024; Madrid, Spain."},{"key":"1355_CR34","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/bjh.19386","volume":"204","author":"AK Nooka","year":"2024","unstructured":"Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, et al. Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. Br J Haematol. 2024;204:2227\u201332.","journal-title":"Br J Haematol"},{"key":"1355_CR35","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Otero P, Moreau P, Dimopoulos MA, Beksac M, Perrot A, Broijl A, et al. Daratumumab (DARA) + bortezomib\/lenalidomide\/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting; May 31\u2013June 4, 2024; Chicago, IL, USA.","DOI":"10.1200\/JCO.2024.42.16_suppl.7502"},{"key":"1355_CR36","unstructured":"SWOG Cancer Research Network. S1803, lenalidomide +\/- daratumumab\/rHuPh20 as post-ASCT maintenance for MM w\/MRD to direct therapy duration (DRAMMATIC). ClinicalTrials.gov ID NCT04071457. https:\/\/clinicaltrials.gov\/study\/NCT04071457. Accessed June 23, 2025."},{"key":"1355_CR37","unstructured":"University of Heidelberg Medical Center. Trial on the effect of isatuximab to lenalidomide\/bortezomib\/dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed myeloma (GMMG HD7). ClinicalTrials.gov ID NCT03617731. https:\/\/www.clinicaltrials.gov\/study\/NCT03617731. Accessed June 23, 2025."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01355-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:07:31Z","timestamp":1759759651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01355-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01355-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LF served on advisory boards and as a site principal investigator for Bristol Myers Squibb, Johnson & Johnson, and Pfizer. LDA served as a consultant and on advisory boards for Johnson & Johnson, Celgene, Bristol Myers Squibb, Amgen, GSK, AbbVie, BeiGene, Cellectar Biosciences, Sanofi, and Prothena; served on the data safety monitoring board for Prothena; and received institutional research funding from Bristol Myers Squibb, AbbVie, Regeneron, Caelum, CARsgen, Cellectar Biosciences, AstraZeneca, Arcellx, and Johnson & Johnson. A Chung served as a consultant and on an advisory board for Bristol Myers Squibb and Johnson & Johnson; and received institutional research funding from AbbVie, Bristol Myers Squibb, Caelum, CARsgen, Cellectis, Johnson & Johnson, K36 Therapeutics, and Merck. CPC received honoraria from Johnson & Johnson and Sanofi\/Genzyme. EP has nothing to declare. AJC served as a consultant or in an advisory role for Sebia, Johnson & Johnson, Bristol Myers Squibb, Sanofi, HopeAI, Adaptive Biotechnologies, and AbbVie; and received institutional research funding from Johnson & Johnson, Bristol Myers Squibb, Juno\/Celgene, Sanofi, Regeneron, IGM Biosciences, Nektar, Harpoon, and Caelum. CC served as a consultant for Bristol Myers Squibb, Johnson & Johnson, Pfizer, Karyopharm, and Genentech; and received institutional research funding from Bristol Myers Squibb, Johnson & Johnson, Takeda, Ionis, Poseida, and Harpoon. SL received institutional research funding from Johnson & Johnson, Allogene, Bioline, Pfizer, Bristol Myers Squibb, Regeneron, Sanofi, Ionis, and ImmPACT Bio; and owns stock or stock options for TORL BioTherapeutics. DWS served as a consultant or in an advisory role for GSK, Johnson & Johnson, Sanofi, AbbVie, Bristol Myers Squibb, Pfizer, Opna Bio, Arcellx, AstraZeneca, and Genentech; and received institutional research funding from Pfizer. KHS served on an advisory board for Bristol Myers Squibb, Johnson & Johnson, Sanofi, and GSK; received institutional research funding from AbbVie and Karyopharm; and received honoraria from Karyopharm, Johnson & Johnson, Adaptive Biotechnologies, GSK, Bristol Myers Squibb, Sanofi\/Genzyme, and Regeneron. RS served as a consultant or in an advisory role for Sanofi, Johnson & Johnson, and Oncopeptides; and received institutional research funding from Sanofi. PV served as a consultant for, received honoraria from, and holds a membership on an entity\u2019s board of directors or advisory committees for AbbVie, Bristol Myers Squibb, Karyopharm, Regeneron, and Sanofi. MK, HP, SP, VK, RC, and TSL are employees of and may hold stock in Johnson & Johnson. A Cortoos is a former employee of and may hold stock in Johnson & Johnson. AB received research funding from Bristol Myers Squibb, GSK, BeiGene, Roche, and Johnson & Johnson.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}